Andres Deik Acosta Madiedo, MD
Neurology · Philadelphia, PANPI 1396907143
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 44.9% of the total.
Across 68 payments — averaging $485.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$15K
- MDD US Operations, LLC$5K
- AbbVie$3K
- Acorda Therapeutics, Inc$3K
- Abbott$2K
- Medtronic$2K
- plus $2K from 4 others
Across 214 payments — averaging $8059.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$605K
- Eli Lilly$412K
- Sunovion Pharmaceuticals Inc.$239K
- H. Lundbeck A S$219K
- Biohaven Pharmaceuticals, Inc.$104K
- Amylyx Pharmaceuticals, Inc.$63K
- plus $82K from 2 others
What the payments were for
- Consulting fees$18,15955%
- Speaking & faculty fees$5,00015%
- Travel & lodging$7,62223%
- Food & beverage$2,1827%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 10 | $14,831 |
| MDD US Operations, LLC | 9 | $5,498 |
| AbbVie(2 entities) | 6 | $3,435 |
| Acorda Therapeutics, Inc | 1 | $2,825 |
| Abbott | 15 | $2,497 |
| Medtronic | 18 | $2,096 |
| Boston Scientific | 4 | $849 |
| Insightec,inc | 1 | $695 |
| Teva Pharmaceuticals USA, Inc. | 3 | $153 |
| Eli Lilly | 1 | $117 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CREXONT$9,636
- GOCOVRI$3,959
- RYTARY$3,500
- INBRIJA$2,825
- BOTOX$2,479
- INFINITY$2,270
- ACTIVA PC$1,399
- MYOBLOC$1,316
- Duopa$833
- GENERAL DBS$798
- PERCEPT PC BRAINSENSE$199
- Austedo XR$100
How this compares
$32,995 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GocovriAmantadine Hcl | 228 | $689,800 |
| RytaryCarbidopa/Levodopa | 236 | $471,656 |
| NuplazidPimavanserin Tartrate | 36 | $227,594 |
| NeuproRotigotine | 94 | $124,726 |
| NourianzIstradefylline | 30 | $84,849 |
| AustedoDeutetrabenazine | 20 | $71,227 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 990 | $51,522 |
| XadagoSafinamide Mesylate | 38 | $48,028 |
| Rasagiline Mesylate | 132 | $23,268 |
| Pramipexole ErPramipexole Di-Hcl | 41 | $20,204 |
| Entacapone | 100 | $19,939 |
| InbrijaLevodopa | 16 | $19,555 |
| Selegiline Hcl | 157 | $17,313 |
| Ropinirole ErRopinirole Hcl | 91 | $16,118 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 225 | $15,860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $5,498 | $689,800228 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont, Pyridostigmine Bromide | $14,831 | $481,468277 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $153 | $71,22720 claims |
| Acorda Therapeutics, IncInbrija | $2,825 | $19,55516 claims |
| AbbVieBotox | $3,435 | $12,31912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.